source
- Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionThe wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.BioPharma Dive · 2mo ago↗ source
- Unmet Needs in Endometrial CancerImportant unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.onclive · 2mo ago↗ source
- EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCsIn this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that…onclive · 2mo ago